Sopris Capital, a leading healthcare investment firm, is entering the drug cost transparency space with a new partnership with RazorMetrics, a rapidly growing healthcare technology company focused on lowering pharmacy costs for at-risk employers and health plans. The Series A investment of $6,000,000 was led by Sopris and other individual investors including long-term entrepreneurs Joel Trammell and Jonathan Weiner.